Literature DB >> 29508083

Ablation Approaches for Ventricular Fibrillation.

Prabhpreet Singh1, Amit Noheria2.   

Abstract

Invasive electrophysiology (EP) mapping and catheter ablation has increasingly become the standard of care for many cardiac arrhythmias like supraventricular tachycardias, atrial fibrillation, premature ventricular complexes (PVC), and monomorphic ventricular tachycardia. In this review, we discuss the recent progress made in the mapping and ablation of ventricular fibrillation (VF). Ventricular activation during VF is apparently disorganized, making mapping and interpretation difficult. Prolonged mapping during VF would require mechanical circulatory support as VF causes complete hemodynamic collapse. These limitations have been addressed by the realization that there is often a reliable trigger arrhythmia that initiates the clinical VF episodes, and an approach to map and ablate this trigger can be successful. Such triggers can be PVCs localizing to the Purkinje/fascicular system, and in other cases can be ectopy from outflow tracts or intracavitary structures like papillary muscles, false tendons or moderator band, or can be monomorphic VT or preexcited atrial fibrillation that degenerate into VF. More recently, approaches beyond trigger elimination directly targeting the VF substrate have been devised. This includes elimination of the arrhythmogenic substrate localizing to the epicardial right ventricular outflow tract in patients with Brugada syndrome, akin to elimination of the arrhythmogenic substrate harbored by regions within scar in ischemic and non-ischemic cardiomyopathies. Further, recent attempts have been made to try to identify and ablate rotors during VF that may be important in perpetuating the VF episode. Such exciting advances in "curing" VF are proving to be life saving for resuscitated survivors of arrhythmic death.

Entities:  

Keywords:  Ablation; Premature ventricular complexes; Ventricular fibrillation

Year:  2018        PMID: 29508083     DOI: 10.1007/s11936-018-0612-4

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  44 in total

Review 1.  Purkinje-related arrhythmias part ii: polymorphic ventricular tachycardia and ventricular fibrillation.

Authors:  Akihiko Nogami
Journal:  Pacing Clin Electrophysiol       Date:  2011-06-15       Impact factor: 1.976

2.  Catheter ablation of ventricular fibrillation storm in patients with infiltrative amyloidosis of the heart.

Authors:  Hanka Mlcochova; Walid I Saliba; David J Burkhardt; Rene E Rodriguez; Jennifer E Cummings; Dhanunjaya Lakkireddy; Dimpi Patel; Andrea Natale
Journal:  J Cardiovasc Electrophysiol       Date:  2006-04

3.  Spontaneous and induced cardiac arrhythmias in subendocardial Purkinje fibers surviving extensive myocardial infarction in dogs.

Authors:  P L Friedman; J R Stewart; A L Wit
Journal:  Circ Res       Date:  1973-11       Impact factor: 17.367

4.  Catheter Ablation of Polymorphic Ventricular Tachycardia and Ventricular Fibrillation.

Authors:  Josef Kautzner; Petr Peichl
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-11-29

5.  Role of Purkinje conducting system in triggering of idiopathic ventricular fibrillation.

Authors:  Michel Haïssaguerre; Dipen C Shah; Pierre Jaïs; Morio Shoda; Josef Kautzner; Thomas Arentz; Dietrich Kalushe; Alan Kadish; Mike Griffith; Fiorenzo Gaïta; Teiichi Yamane; Stephane Garrigue; Meleze Hocini; Jacques Clémenty
Journal:  Lancet       Date:  2002-02-23       Impact factor: 79.321

6.  Use of stored implanted cardiac defibrillator electrograms in catheter ablation of ventricular fibrillation.

Authors:  Christopher M Lowery; Wendy S Tzou; Ryan G Aleong; Duy T Nguyen; Paul D Varosy; David F Katz; Russell R Heath; Joseph L Schuller; Laurent Lewkowiez; William H Sauer
Journal:  Pacing Clin Electrophysiol       Date:  2012-10-18       Impact factor: 1.976

7.  Relevance of endocavitary structures in ablation procedures for ventricular tachycardia.

Authors:  Omar Abouezzeddine; Mahmoud Suleiman; Traci Buescher; Suraj Kapa; Paul A Friedman; Arshad Jahangir; Jennifer A Mears; Dorothy J Ladewig; Thomas M Munger; Stephen C Hammill; Douglas L Packer; Samuel J Asirvatham
Journal:  J Cardiovasc Electrophysiol       Date:  2009-10-08

8.  Mode of initiation and ablation of ventricular fibrillation storms in patients with ischemic cardiomyopathy.

Authors:  Nassir F Marrouche; Atul Verma; Oussama Wazni; Robert Schweikert; David O Martin; Walid Saliba; Fethi Kilicaslan; Jennifer Cummings; J David Burkhardt; Mandeep Bhargava; Dianna Bash; Johannes Brachmann; Jens Guenther; Steven Hao; Salwa Beheiry; Antonio Rossillo; Antonio Raviele; Sakis Themistoclakis; Andrea Natale
Journal:  J Am Coll Cardiol       Date:  2004-05-05       Impact factor: 24.094

9.  Elimination of local abnormal ventricular activities: a new end point for substrate modification in patients with scar-related ventricular tachycardia.

Authors:  Pierre Jaïs; Philippe Maury; Paul Khairy; Frédéric Sacher; Isabelle Nault; Yuki Komatsu; Mélèze Hocini; Andrei Forclaz; Amir S Jadidi; Rukshen Weerasooryia; Ashok Shah; Nicolas Derval; Hubert Cochet; Sebastien Knecht; Shinsuke Miyazaki; Nick Linton; Lena Rivard; Matthew Wright; Stephen B Wilton; Daniel Scherr; Patrizio Pascale; Laurent Roten; Michala Pederson; Pierre Bordachar; François Laurent; Steven J Kim; Philippe Ritter; Jacques Clementy; Michel Haïssaguerre
Journal:  Circulation       Date:  2012-04-04       Impact factor: 29.690

Review 10.  Ventricular tachycardia ablation and substrate modification in ICD patients with electrical storm.

Authors:  Minglong Chen
Journal:  J Biomed Res       Date:  2015-01-15
View more
  2 in total

Review 1.  [History of catheter ablation].

Authors:  Dietrich Pfeiffer; Jürgen Tebbenjohanns; Norbert Klein; Michael Metze; Martin Neef
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2019-11-22

Review 2.  Handling of Ventricular Fibrillation in the Emergency Setting.

Authors:  Zoltán Szabó; Dóra Ujvárosy; Tamás Ötvös; Veronika Sebestyén; Péter P Nánási
Journal:  Front Pharmacol       Date:  2020-01-29       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.